Last reviewed · How we verify
Aspart fixed dose
Aspart fixed dose is a marketed drug developed by Kathleen Dungan, with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a significant competitive advantage due to its patent protection until 2028. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Aspart fixed dose |
|---|---|
| Also known as | Novolog |
| Sponsor | Kathleen Dungan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (PHASE1)
- HbA1c Variability in Type II Diabetes (NA)
- A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus (PHASE1)
- Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil (PHASE1)
- A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus (PHASE4)
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (PHASE4)
- Prandial Insulin Dosing in Hospitalized Patients (PHASE4)
- Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspart fixed dose CI brief — competitive landscape report
- Aspart fixed dose updates RSS · CI watch RSS
- Kathleen Dungan portfolio CI